Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Advanced Breast Cancer”

728 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 728 results

Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06750848
What this trial is testing

Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jundong Wu 48
Not applicableUnknownNCT04683757
What this trial is testing

The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Ying Wang 288
Large-scale testing (Phase 3)Active Not RecruitingNCT04191499
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 325
Large-scale testing (Phase 3)Active Not RecruitingNCT05306340
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Who this might be right for
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Genentech, Inc. 373
Large-scale testing (Phase 3)Study completedNCT02586025
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

Who this might be right for
Breast Cancer
Hoffmann-La Roche 329
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Testing effectiveness (Phase 2)WithdrawnNCT01658176
What this trial is testing

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT07180082
What this trial is testing

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Wenjin Yin 186
Large-scale testing (Phase 3)Ended earlyNCT02730091
What this trial is testing

A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon 98
Testing effectiveness (Phase 2)Ended earlyNCT05583110
What this trial is testing

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
Spanish Breast Cancer Research Group 13
Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing

PF-06873600 in People With Cancer

Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155
Early research (Phase 1)Study completedNCT04132817
What this trial is testing

Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 12
Testing effectiveness (Phase 2)Ended earlyNCT05555251
What this trial is testing

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Metastatic Breast Cancer+2 more
BioInvent International AB 18
Not applicableStudy completedNCT06525675
What this trial is testing

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerLuminal Breast Cancer+2 more
MedSIR 419
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06339281
What this trial is testing

Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Li Huiping 68
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Large-scale testing (Phase 3)Active Not RecruitingNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Early research (Phase 1)Study completedNCT03650348
What this trial is testing

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 41
Load More Results